SRF and myocardin regulate LRP-mediated amyloid-β clearance in brain vascular cells
Open accessThe DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Amyloid beta-peptide (Abeta) deposition in cerebral vessels contributes to cerebral amyloid angiopathy (CAA) in Alzheimer's disease (AD). Here, we report that in AD patients and two mouse models of AD, overexpression of serum response factor (SRF) and myocardin (MYOCD) in cerebral vascular smooth muscle cells (VSMCs) generates an Abeta non-clearing VSMC phenotype through transactivation of sterol regulatory element binding protein-2, which downregulates low density lipoprotein receptor-related protein-1, a key Abeta clearance receptor. Hypoxia stimulated SRF/MYOCD expression in human cerebral VSMCs and in animal models of AD. We suggest that SRF and MYOCD function as a transcriptional switch, controlling Abeta cerebrovascular clearance and progression of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the low-density lipoprotein receptor–related protein-1, a critical Aβ brain clearance receptor, is downregulated in cerebral blood vessels of patients with Alzheimer disease, leading to accumulation of amyloid around blood vessels and worsening of vascular dysfunction.129”
From Vascular Contributions to Cognitive Impairment and Dementia: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association (2011) · cites this paper as [129]
Experimental — accuracy not yet measuredIn the citing paper
“In particular, suppression of LRP1 in vascular smooth muscle cells due to upregulation of serum response factor and myocardin, is a key factor in the clearance impairment (Bell et al., 2009).”
From The Pathobiology of Vascular Dementia (2013) · cites this paper as Bell et al., 2009
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744
Brown, M. S., & Goldstein, J. L. (1997) · Cell · doi:10.1016/s0092-8674(00)80213-5 · Cited by 3,834
The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280 · cited 1×
“dtd" [ ]> Dementia in Alzheimer's disease (AD) is associated with neurovascular dysfunctio”
Silent Brain Infarcts and the Risk of Dementia and Cognitive Decline
Vermeer, S. E., Prins, N. D., den Heijer, T., Hofman, A., Koudstaal, P. J., & Breteler, M. M. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022066 · Cited by 2,313
Neurovascular regulation in the normal brain and in Alzheimer's disease
Iadecola, C. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1387 · Cited by 2,213 · cited 1×
“dtd" [ ]> Dementia in Alzheimer's disease (AD) is associated with neurovascular dysfunctio”
Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413 · cited 1×
“The low-density lipoprotein receptor-related protein 1 (LRP) is a major Aβ clearance receptor at the BB”
BackgroundWolozin, B. (2000) · Archives of Neurology · doi:10.1001/archneur.57.10.1439 · Cited by 1,398 · cited 1×
“Previous studies have shown that people chronically treated with cholesterol-lowering drugs, such as statins, are less prone to develop A”
BackgroundAdult mouse astrocytes degrade amyloid-β in vitro and in situ
Wyss-Coray, T., Loike, J. D., Brionne, T. C., Lu, E., Anankov, R., Yan, F., Silverstein, S. C., & Husemann, J. (2003) · Nature Medicine · doi:10.1038/nm838 · Cited by 909
Wang, D.-Z., Chang, P. S., Wang, Z., Sutherland, L., Richardson, J. A., Small, E., Krieg, P. A., & Olson, E. N. (2001) · Cell · doi:10.1016/s0092-8674(01)00404-4 · Cited by 898
LRP/Amyloid β-Peptide Interaction Mediates Differential Brain Efflux of Aβ Isoforms
Deane, R., Wu, Z., Sagare, A., Davis, J., Du Yan, S., Hamm, K., Xu, F., Parisi, M., LaRue, B., Hu, H. W., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.07.017 · Cited by 828
Self-citation
Research works printed but not linked: 1
- Holtzman, D. M. et al. Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model. Ann. Neurol. 47, 739–747 (2000). · doi:10.1002/1531-8249(200006)47:6<739::aid-ana6>3.0.co;2-8
Cited by
Items 101–200 of 262
Longitudinal modeling of cognitive aging and the TOMM40 effect
Caselli, R. J., Dueck, A. C., Huentelman, M. J., Lutz, M. W., Saunders, A. M., Reiman, E. M., & Roses, A. D. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.11.006 · Cited by 69
“Oxidative stress [2], vascular endothelial dysfunction [3], hypoxia [4], glucose deprivation [5], and mitochondrial dysfunction [6] all promote amyloidogenesis.”
BackgroundStorck, S. E., & Pietrzik, C. U. (2017) · Pharmaceutical Research · doi:10.1007/s11095-017-2267-3 · Cited by 79
“As LRP1 expression and processing is influenced by various factors like, hypoxia (122), aging (66,119), Aβ exposure (127), and hypoglycemia (128)”
BackgroundThe Role of Cholesterol Metabolism in Alzheimer’s Disease
Sun, J.-H., Yu, J.-T., & Tan, L. (2015) · Molecular Neurobiology · doi:10.1007/s12035-014-8749-y · Cited by 70
Amylin alters human brain pericyte viability and NG2 expression
Schultz, N., Byman, E., Fex, M., & Wennström, M. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x16657093 · Cited by 72
“We further found no co-localization between microvessel-associated amylin cell inclusions and Ab.”
ResultInfluentialAddressing Blood–Brain Barrier Impairment in Alzheimer’s Disease
Sharma, C., Woo, H., & Kim, S. R. (2022) · Biomedicines · doi:10.3390/biomedicines10040742 · Cited by 68
Amyloid beta accumulation in HIV‐1‐infected brain: The role of the blood brain barrier
András, I. E., & Toborek, M. (2013) · IUBMB Life · doi:10.1002/iub.1106 · Cited by 65
“ApoJ, a ligand for the LRP2 (or megalin) not only controls Ab transcytosis across the BBB, facilitating an efflux from the brain to blood (44) but can also mediate re-entry of circulating Ab into the brain (45).”
BackgroundDissecting the Contribution of Vascular Alterations and Aging to Alzheimer’s Disease
Janota, C. S., Lemere, C. A., & Brito, M. A. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9319-7 · Cited by 77
“These two factors are responsible to promote the vascular smooth muscle cells (VSMC) hypercontractile phenotype and their activity results in hypoperfusion and cerebral amyloid angiopathy (CAA) [85].”
BackgroundAging alters mRNA expression of amyloid transporter genes at the blood-brain barrier
Osgood, D., Miller, M. C., Messier, A. A., Gonzalez, L., & Silverberg, G. D. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.05.011 · Cited by 63
“nonclearing vascular smooth muscle cell phenotype through transactivation of sterol regulatory element binding protein-2, which downregulates LRP-1 (Bell et al., 2009).”
Do, T. M., Dodacki, A., Alata, W., Calon, F., Nicolic, S., Scherrmann, J.-M., Farinotti, R., & Bourasset, F. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-150350 · Cited by 60
Vascular pathology and pathogenesis of cognitive impairment and dementia in older adults
Agrawal, S., & Schneider, J. A. (2022) · Cerebral Circulation - Cognition and Behavior · doi:10.1016/j.cccb.2022.100148 · Cited by 76
Vascular smooth muscle cell dysfunction in neurodegeneration
Hayes, G., Pinto, J., Sparks, S., Wang, C., Suri, S., & Bulte, D. P. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.1010164 · Cited by 67
“Studies have reported that in patients with AD and mouse models of AD, the overexpression of molecules that control the rate of cell transcript in cerebral VSMCs generates a hypercontractile VSMC phenotype with reduced clearance receptors for the notorious amyloid-beta (Aβ) peptides (Chow et al., 2007; Bell et al., 20…”
BackgroundAnwar, M. M., Özkan, E., & Özdemir, Y. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.15372 · Cited by 60
“Thus, the reduced LRP1 level in AD patients is associated with elevated APOE3–Aβ complexes leading to BBB dysfunction and Aβ aggregations in the brain (Bell et al., 2009; Ramanathan et al., 2015; Tarasoff-Conway et al., 2015; Zlokovic et al., 2010) (Figure 2).”
BackgroundIs Beta-Amyloid Accumulation a Cause or Consequence of Alzheimer's Disease?
Wang, S., Mims, P. N., Roman, R. J., & Fan, F. (2016) · PubMed · Cited by 63
Ito, S., Ueno, T., Ohtsuki, S., & Terasaki, T. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06708.x · Cited by 48
Au, D. T., Strickland, D. K., & Muratoglu, S. C. (2017) · Journal of Diabetes Research · doi:10.1155/2017/8356537 · Cited by 51
“This effect of GLUT1 on LRP1 expression was connected to increased levels of the sterol regulatory element binding protein 2 (SREBP2), which is a known transcriptional suppressor of LRP1 [63].”
BackgroundEnergy and the Alzheimer brain
Mamelak, M. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.02.001 · Cited by 53
He, Y., Ruganzu, J. B., Jin, H., Peng, X., Ji, S., Ma, Y.-B., Zheng, L.-M., & Yang, W.-N. (2020) · Experimental Cell Research · doi:10.1016/j.yexcr.2020.112166 · Cited by 41
A Murine Toolbox for Imaging the Neurovascular Unit
Hartmann, D. A., Underly, R. G., Watson, A. N., & Shih, A. Y. (2014) · Microcirculation · doi:10.1111/micc.12176 · Cited by 46
“SMCs also have important signaling and transport roles in the brain, the disruption of which is involved in pathologies such as arteriovenous malformations and cerebral amyloid angiopathy [10,143].”
BackgroundHe, Y., Ruganzu, J. B., Zheng, Q., Wu, X., Jin, H., Peng, X., Ding, B., Lin, C., Ji, S., Ma, Y., et al. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-01982-7 · Cited by 51
Zabel, M., Schrag, M., Crofton, A., Tung, S., Beaufond, P., Van Ornam, J., DiNinni, A., Vinters, H. V., Coppola, G., & Kirsch, W. M. (2013) · Brain Pathology · doi:10.1111/bpa.12005 · Cited by 46
“propagate activation to the MAC (4), which would be even more pro-”
BackgroundData-driven modeling of Alzheimer Disease pathogenesis
Anastasio, T. J. (2011) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2011.08.038 · Cited by 48
Girolamo, F., de Trizio, I., Errede, M., Longo, G., d’Amati, A., & Virgintino, D. (2021) · Fluids and Barriers of the CNS · doi:10.1186/s12987-021-00242-7 · Cited by 49
Cooper, L. L., O’Donnell, A., Beiser, A., Thibault, E. G., Sanchez, J. S., Benjamin, E. J., Hamburg, N. M., Vasan, R. S., Larson, M. G., Johnson, K. A., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.1261 · Cited by 47
P2Y receptors in Alzheimer's disease
Erb, L., Cao, C., Ajit, D., & Weisman, G. A. (2015) · Biology of the Cell · doi:10.1111/boc.201400043 · Cited by 43
“, 2007), serum response factor and myocardin (transcription factors that suppress expression of LRP1, a major transporter of Aβ from vascular cells in the brain to the bloodstream) (Chow et al., 2007; Bell et al., 2009) and PERK (an endoplasmic reticulum kinase that deactivates translation initiation factor eIF2α and…”
BackgroundInfluentialLoss of Calreticulin Uncovers a Critical Role for Calcium in Regulating Cellular Lipid Homeostasis
Wang, W., Liu, W., Durnaoglu, S., Lee, S.-K., Lian, J., Lehner, R. S., Ahnn, J., Agellon, L. B., & Michalak, M. (2017) · Scientific Reports · doi:10.1038/s41598-017-05734-x · Cited by 44
McMillan, I. O., Li, J., & Wang, L. (2023) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00247.2022 · Cited by 51
DeCarli, C. S., Kawas, C. H., Morrison, J. H., Reuter‐Lorenz, P. A., Sperling, R. A., & Wright, C. B. (2012) · The Journals of Gerontology Series A · doi:10.1093/gerona/gls111 · Cited by 73
Sagare, A. P., Bell, R. D., Srivastava, A., Sengillo, J. D., Singh, I., Nishida, Y., Chow, N., & Zlokovic, B. V. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.439570 · Cited by 40
“Down-regulation of LRP1 at the BBB due to vascular risk factors and/or oxidative stress (17, 64), oxidation, or reduced levels of sLRP1 in plasma (14) and reduced expression of LRP1 in the liver (65) lead to accumulation of A in brain in different experimental models.”
BackgroundSelf-citationVascular mTOR-dependent mechanisms linking the control of aging to Alzheimer's disease
Galvan, V., & Hart, M. J. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.11.010 · Cited by 40
Reduction of Circulating Endothelial Cells in Peripheral Blood of ALS Patients
Garbuzova-Davis, S. N., Woods, R. L., Louis, M. K., Zesiewicz, T. A., Kuzmin‐Nichols, N., Sullivan, K. L., Miller, A. M., Hernandez‐Ontiveros, D. G., & Sanberg, P. R. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010614 · Cited by 43
“It has been shown, for example, that overexpression of the two transcription factors, serum response factor and myocardin, in the cerebral vascular smooth muscle cells in AD, mediated arterial hypercontractility leading to reduced cerebral blood flow [48] and facilitated cerebral amyloid angiopathy via accumulation of…”
Blood-Brain Barrier Disruption: A Common Driver of Central Nervous System Diseases
Segura‐Collar, B., Mata-Martínez, P., Hernández‐Laín, A., Gómez, P. S., & Gargini, R. (2021) · The Neuroscientist · doi:10.1177/1073858420985838 · Cited by 43
Myocardin and smooth muscle differentiation
Zheng, X. (2013) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2013.12.015 · Cited by 39
Lu, X., Moeini, M., Li, B., de Montgolfier, O., Lu, Y., Bélanger, S., Thorin, É., & Lesage, F. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.11.015 · Cited by 36
Lee, J., Lee, H., Lee, H. G., Shin, M., Shin, M.-G., Seo, J., Lee, E. J., Park, S. A., & Park, S. (2023) · Nature Communications · doi:10.1038/s41467-023-44319-3 · Cited by 42
Cheung, C., Goh, Y. T., Zhang, J., Wu, C., & Guccione, E. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.08.065 · Cited by 35
“Internalization of Ab by lipoprotein receptors on SMCs was reported to be compromised by hypoxic conditions (Bell et al., 2009).”
BackgroundLong non-coding RNAs in neurodegenerative diseases
Yang, S., Yang, H., Luo, Y., Deng, X., Zhou, Y., & Hu, B. (2021) · Neurochemistry International · doi:10.1016/j.neuint.2021.105096 · Cited by 34
Li, J., Han, L., Wen, Y.-X., Yang, Y., Li, S., Li, X.-S., Zhao, C., Wang, T., Chen, H., Liu, Y., et al. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-141215 · Cited by 40
Ruzali, W. A. W., Kehoe, P. G., & Love, S. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-121336 · Cited by 34
Vascular factors and epigenetic modifications in the pathogenesis of Alzheimer's disease
Leszek, J., Sochocka, M., & Gąsiorowski, K. (2012) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2012.09.010 · Cited by 35
Mitochondrial mechanisms in amyloid beta peptide-induced cerebrovascular degeneration
Hsu, M., Sheu, J., Lin, C., Shen, M., & Hsu, C. Y. (2009) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2009.08.003 · Cited by 39
The Imbalance of Vascular Molecules in Alzheimer's Disease
Bell, R. D. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-121060 · Cited by 34
Self-citationZhang, H., Wang, Z. ‐., Chen, F. ‐., Ding, W., Liu, W., Chen, Z., He, S. ‐., & Wei, A. (2017) · Andrology · doi:10.1111/andr.12375 · Cited by 33
“Phenotypic switching in vascular smooth muscle cells (VSMCs), defined as the ability to transform from the contractile phenotype to the synthetic phenotype reversibly (Lacolley et al., 2012), has been studied in depth and has been shown to be one of the most important molecular mechanisms underlying multiple cardiovas…”
ResultInfluentialThe Blood-Brain Barrier in Alzheimer’s Disease
Storck, S. E., Hartz, A. M. S., & Pietrzik, C. U. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_418 · Cited by 32
Gren, M., Shahim, P., Lautner, R., Wilson, D. H., Andréasson, U., Norgren, N., Blennow, K., & Zetterberg, H. (2016) · Brain Injury · doi:10.1080/02699052.2016.1179792 · Cited by 35
Kurata, T., Kawai, H., Miyazaki, K., Kozuki, M., Morimoto, N., Ohta, Y., Ikeda, Y., & Abe, K. (2012) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2012.06.011 · Cited by 35
“Alterations in Aβ clearance across the blood brain barrier (BBB) play a major role in brain Aβ accumulation [5], and decreased Aβ clearance has been shown to facilitate accumulation of Aβ in the brain and allow for the progression of AD [6].”
BackgroundRegulation of β-amyloid level in the brain of rats with cerebrovascular hypoperfusion
Liu, H., Xing, A., Wang, X., Liu, G., & Li, L. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.05.027 · Cited by 38
Paris, D., Ganey, N., Banasiak, M., Laporte, V., Patel, N., Mullan, M., Murphy, S. F., Yee, G.-T., Bachmeier, C., Ganey, C., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.2586-10.2010 · Cited by 30
“…brain vascular cells and may initiate a pathogenic cascade resulting in hypercontractility of cerebral arterioles, CBF reduction (Chow et al., 2007) and decreased A clearance across the BBB, consequently facilitating the pathological accumulation of A and the progression of AD (Bell et al., 2009).”
BackgroundFan, Y., Guo, T., Han, X., Liu, J.-L., Cai, Y.-T., Han, X., Huang, X., Li, Y., Wang, Z., & Guo, C. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.07.014 · Cited by 28
“SREBP2 is recognized as the only transcriptional repressor of LRP1, and increased nuclear SREBP2 expression leads to LRP1 downregulation,which impairs Aβ clearance in Alzheimer's disease patients [65].”
BackgroundKurata, T., Miyazaki, K., Kozuki, M., Morimoto, N., Ohta, Y., Ikeda, Y., & Abe, K. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.09.030 · Cited by 34
La barrière hémato-encéphalique: Une nouvelle cible thérapeutique dans la maladie d’Alzheimer ?
Gosselet, F., Candela, P., Cecchelli, R., & Fénart, L. (2011) · médecine/sciences · doi:10.1051/medsci/20112711015 · Cited by 49
Protection of the Blood-Brain Barrier by Pentosan Against Amyloid-β-Induced Toxicity
Deli, M. A., Veszelka, S., Csiszár, B., Tóth, A. E., Kittel, Á., Csete, M., Sipos, Á., Szalai, A., Fülöp, L., Penke, B., et al. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100759 · Cited by 33
Wang, X., Li, H., Sheng, Y., He, B., Liu, Z., Li, W., Yu, S., Wang, J., Zhang, Y., Chen, J., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.116071 · Cited by 29
Consideration of the ischaemic basis and treatment of Alzheimer's disease.
Pluta, R. M., Ułamek, M., & Jabłoński, M. (2010) · PubMed · Cited by 30
Robert, J., Button, E. B., Martin, E. M., McAlary, L., Gidden, Z., Gilmour, M., Boyce, G., Caffrey, T. M., Agbay, A., Clark, A., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00366-8 · Cited by 27
“Furthermore, Bell and colleagues elegantly showed that overexpression of serum response factor and myocardin in SMC reduces LRP1 expression, induces arterial hypercontractility, and reduces cerebral blood flow (CBF), ultimately leading to increased CAA in mice [57].”
BackgroundOxygen Sensing: A Common Crossroad in Cancer and Neurodegeneration
Quaegebeur, A., & Carmeliet, P. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_83 · Cited by 33
“Moreover, increased levels of SRF and MYOCD in AD brain result in downregulation of LRP (Bell et al. 2009), a key receptor of transendothelial Ab transport.”
BackgroundSagare, A. P., Winkler, E. A., Bell, R. D., Deane, R., & Zloković, B. V. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22670 · Cited by 35
“, 2004) and in vascular smooth muscle cells of small cerebral arteries (Bell et al., 2009) and has been demonstrated to mediate the removal of brain Ab into the circulation (for review see Zlokovic et al, 2010).”
BackgroundSelf-citationDefective vascular signaling & prospective therapeutic targets in brain arteriovenous malformations
Winkler, E. A., Lu, A. Y., Raygor, K. P., Linzey, J. R., Jonzzon, S., Lien, B. V., Rutledge, C., & Abla, A. A. (2019) · Neurochemistry International · doi:10.1016/j.neuint.2019.03.002 · Cited by 28
MethReg: estimating the regulatory potential of DNA methylation in gene transcription
Silva, T. C., Young, J. I., Martin, E. R., Chen, X. S., & Wang, L. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac030 · Cited by 32
“Compared with healthy individuals, SRF was found to be four times higher in AD patients [122, 123].”
BackgroundAlzheimer's dementia by circulation disorders: when trees hide the forest
Dotti, C. G., & Strooper, B. D. (2009) · Nature Cell Biology · doi:10.1038/ncb0209-114 · Cited by 30
Oue, H., Yamazaki, Y., Qiao, W., Yuanxin, C., Ren, Y., Kurti, A., Shue, F., Parsons, T. M., Perkerson, R. B., Kawatani, K., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.163822 · Cited by 31
The pericyte: A critical cell in the pathogenesis of CADASIL
Ruchoux, M., Kalaria, R. N., & Román, G. C. (2021) · Cerebral Circulation - Cognition and Behavior · doi:10.1016/j.cccb.2021.100031 · Cited by 38
Alzheimer’s Silent Partner: Cerebral Amyloid Angiopathy
Cupino, T. L., & Zabel, M. K. (2013) · Translational Stroke Research · doi:10.1007/s12975-013-0309-7 · Cited by 32
“Depressed LRP-1 follows overexpression of myocardin and serum response factor which together downregulate LRP-1 via activation of sterol regulatory element binding protein-2 (SREBP2) [57, 58].”
Ferreira, L. K., Tamashiro-Duran, J. H., Squarzoni, P., Duran, F., Alves, T. C. T. F., Buchpiguel, C. A., & Busatto, G. F. (2014) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2013-1275 · Cited by 27
Soluble guanylyl cyclase: A novel target for the treatment of vascular cognitive impairment?
Nelissen, E., Schepers, M., Ponsaerts, L., Foulquier, S., Bronckaers, A., Vanmierlo, T., Sandner, P., & Prickaerts, J. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106970 · Cited by 26
Ruzali, W. A. W., Kehoe, P. G., & Love, S. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.07.065 · Cited by 26
Zhang, H., Chen, F.-Z., He, S., Liang, Y.-B., Wang, Z.-Q., Wang, L., Chen, Z., Ding, W., Zhao, S., & Wei, A. (2019) · Stem Cell Research & Therapy · doi:10.1186/s13287-019-1325-7 · Cited by 22
“In our study, myocardin, which has been confirmed to be essential for the development and function of smooth muscle cells [32, 33], was introduced to induce the differentiation of ASCs towards SML cells in vitro by interacting with SRF and inhibiting the general stem cell markers SOX2 and OCT4 [34], as well as enhanci…”
Wesolowska, N., & Lénárt, P. (2015) · Chromosoma · doi:10.1007/s00412-015-0519-8 · Cited by 24
“MRTF’s involvement in regulation of contractile proteins (Xing et al. 2006; Bell et al. 2009), and cancer metastasis, through its critical function in cell migration (Brandt et al.”
BackgroundContributions of Drug Transporters to Blood-Brain Barriers
Liu, L., & Liu, X. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-7647-4_9 · Cited by 21
Peripheral Pathways to Neurovascular Unit Dysfunction, Cognitive Impairment, and Alzheimer’s Disease
Nelson, A. R. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.858429 · Cited by 25
Amyloid Beta Influences Vascular Smooth Muscle Contractility and Mechanoadaptation
Hald, E. S., Timm, C. D., & Alford, P. W. (2016) · Journal of Biomechanical Engineering · doi:10.1115/1.4034560 · Cited by 22
Recombinant Adeno-Associated Virus-Mediated Delivery of MicroRNA-21-3p Lowers Hypertension
Wang, F., Fang, Q., Chen, C., Zhou, L., Li, H., Yin, Z., Wang, Y., Zhao, C. X., Xiao, X., & Wang, D. W. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.11.007 · Cited by 21
“As shown in Figures 6K and 6L, overexpression of SRF by the pcDNA 3.1-SRF plasmid significantly increased the expressions of precursormiR-21 and mature miR-21-3p in VSMCs.”
MethodInfluentialRuan, Q., Yu, Z., Zhang, W., Ruan, J., Liu, C., & Zhang, R. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00098 · Cited by 24
“, 2007), decreased Aβ clearance due to loss or oxidization of lipoprotein receptors in endothelial cells and astrocytes (Bell et al., 2009; Owen et al., 2010), Reduced glutamate reuptake by astrocytes (Boycott et al.”
BackgroundMegakaryocytic Leukemia 1 (MKL1) Regulates Hypoxia Induced Pulmonary Hypertension in Rats
Yuan, Z., Chen, J., Chen, D., Xu, G., Xia, M., Xu, Y., & Gao, Y. (2014) · PLoS ONE · doi:10.1371/journal.pone.0083895 · Cited by 24
Amyloid-β: A potential mediator of aging-related vascular pathologies
Khan, F., & Qiu, H. (2023) · Vascular Pharmacology · doi:10.1016/j.vph.2023.107213 · Cited by 22
Ding, X., Zhou, S., Li, M., Cao, C., Wu, P., Sun, L., Fei, G., & Wang, R. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25922 · Cited by 21
“Hypoxia substantially elevated expression level of SRF by sixfold in cultured human VSMCs, but decreased LRP expression [Bell et al., 2009].”
BackgroundYang, C., Mo, Y., Chen, H., Huang, Y., Li, S., Wang, H., Huang, S., Chang, X., Du, Q., & Wang, Q. (2021) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2002025 · Cited by 21
“In animal and AD patients, the level of LRP1 is decreased [33, 34].”
BackgroundVromman, A., Trabelsi, N., Rouxel, C., Bereziat, G., Limon, I., & Blaise, R. (2013) · Aging Cell · doi:10.1111/acel.12056 · Cited by 22
“This phenomenon, associated with VSMCs de-differentiation ultimately leading to VSMCs degeneration could cause, or at least aggravate, the vascular alterations characteristic of CAA, resulting in hemorrhage, cerebral hypo-perfusion, and stroke.”
ResultInfluentialO'Callaghan, P. W., Noborn, F., Sehlin, D., Li, J., Lannfelt, L., Lindahl, U., & Zhang, X. (2014) · Amyloid · doi:10.3109/13506129.2013.879643 · Cited by 20
“Furthermore, the LRP1-dependence of Ab association with the cells supports previous reports that decreased LRP1 expression correlates with impaired Ab uptake and efflux [9,15].”
BackgroundThe Role of Astrocytes and Blood–Brain Barrier Disruption in Alzheimer’s Disease
Cruz, J. V. R., Batista, C., Diniz, L. P., & Mendes, F. A. (2023) · Neuroglia · doi:10.3390/neuroglia4030015 · Cited by 20
“…Ca 2+ homeostasis genes that are regulated by SRF/MYOD, resulting in cerebral hypoperfusion, diminished neurovascular coupling, and transactivation of SREBP2, a transcriptional suppressor of LRP1, reducing LRP1 expression and diminishing A β clearance via VSMCs in small penetrating vessels [37].”
BackgroundInteractions between Beta-Amyloid and Pericytes in Alzheimer’s Disease
Li, Y.-Y., Guo, D.-D., Duan, R., & Li, Y. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2904136 · Cited by 19
“The process of clearing A β by pericytes can be inhibited by antibodies against LRP-1 [80,84], further confirming that the clearance of A β is mediated by LRP-1 (Fig.”
BackgroundMolecular signature and functional properties of human pluripotent stem cell-derived brain pericytesPreprint
Rust, R., Sagare, A. P., Kisler, K., Kim, Y., Zhang, M., Griffin, C., Wang, Y., Clementel, V. A., Shwartz, A., Fraser, S. E., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.06.26.546577 · Cited by 18
“The Shandon multi-spot microscope glass slides (Thermo Scientific, 9991090) were coated with Cy3-labelled human Aβ42 at 5 µg per spot, as described previously 32,33,60 .”
Self-citationAutophagy in alzheimer disease pathogenesis and its therapeutic values
Angst, G., Jia, N., Esqueda, L. T., Fan, Y., Cai, Q., & Wang, C. (2025) · Autophagy Reports · doi:10.1080/27694127.2025.2471677 · Cited by 25
Identification of key lipid metabolism-related genes in Alzheimer’s disease
Zeng, Y., Cao, S., Li, N., Tang, J., & Lin, G. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01918-9 · Cited by 20
“This implies that SRF and myocardin could potentially govern Aβ cerebrovascular clearance and influence AD progression [74].”
BackgroundTorrado, M., Iglesias, R., Centeno, A., López, E., & Mikhailov, A. T. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026392 · Cited by 15
“Upregulation of myocd enforces cardiac hypertrophic response [21,22,25], antagonizes cell proliferation in growthand tumor-related processes [54,55,56], and in some situations promotes hypercontractile vascular phenotype that may contribute to neurovascular dysfunction [57,58].”
BackgroundWinkler, E. A., Pacult, M. A., Catapano, J. S., Scherschinski, L., Srinivasan, V. M., Graffeo, C. S., Oh, S. P., & Lawton, M. T. (2022) · Neurosurgical FOCUS · doi:10.3171/2022.4.focus2291 · Cited by 15
Tamashiro-Duran, J. H., Squarzoni, P., Duran, F., Curiati, P. K., Vallada, H., Buchpiguel, C. A., Lotufo, P. A., Wajngarten, M., Menezes, P. R., Scazufca, M., et al. (2012) · AGE · doi:10.1007/s11357-012-9413-y · Cited by 14
Knöll (2011) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2011.00049 · Cited by 18
Developing Trojan horses to induce, diagnose and suppress Alzheimer’s pathology
Aziz, A. A., & Amtul, Z. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104471 · Cited by 15
Blood–Brain Barrier Transport of Alzheimer’s Amyloid β-Peptide
Nelson, A. R., Sagare, A. P., & Zloković, B. V. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00009-5 · Cited by 14
Self-citationNakajo, Y., Yang, D. W., TAKAHASHI, J. C., Zhao, Q., Kataoka, H., & Yanamoto, H. (2015) · Brain Research · doi:10.1016/j.brainres.2015.03.042 · Cited by 13
Cuzzo, L. M., Ross‐Cisneros, F. N., Yee, K. M. P., Wang, M. Y., & Sadun, A. A. (2011) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0b013e31821b602c · Cited by 10
“interacting with APP in the endoplasmic reticulum (ER) (52).”
BackgroundVascular α1A Adrenergic Receptors as a Potential Therapeutic Target for IPAD in Alzheimer’s Disease
Frost, M., Keable, A., Baseley, D., Sealy, A., Zbarcea, D. A., Gatherer, M., Yuen, H. M., Sharp, M. M., Weller, R. O., Attems, J., et al. (2020) · Pharmaceuticals · doi:10.3390/ph13090261 · Cited by 11
“Increased levels of myocardin and serum response factor in blood vessels in CAA may reflect a decrease in the function of SMCs and clearance of Aβ [16,17].”
BackgroundWu, J., Zhu, S., Zhao, C., & Xu, X. (2022) · Current Alzheimer Research · doi:10.2174/1567205019666220202120638 · Cited by 11
LRP1 at the crossroads of Aβ clearance and therapeutic targeting in Alzheimer’s disease
Deng, Y., Yin, H., Lu, Z., Lan, H., Liu, W., Zuo, C., Pan, N., Tian, X., & Gong, Q. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1669405 · Cited by 16
Liu, S. J., Li, X., Fan, P., Gu, Y., Yang, A., Wang, W., Zhou, L., Chen, H., Zheng, F., Lin, J., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117575 · Cited by 13
High pulse pressure is a risk factor for prodromal Alzheimer’s disease: a longitudinal study
Shi, W., Initiative, A. D. N., Wang, Z.-T., Sun, F.-R., Ma, Y., Xu, W., Shen, X., Dong, Q., Tan, L., Yu, J., et al. (2020) · Aging · doi:10.18632/aging.103678 · Cited by 10
“Besides, some studies suggest that circulatory injuries, such as those caused by stiffening of the vasculature system, may result in failure of clearance of Aβ from the brain [31].”
BackgroundA single cell brain atlas in human Alzheimer’s diseasePreprint
Grubman, A., Chew, G., Ouyang, J. F., Sun, G., Choo, X. Y., McLean, C., Simmons, R. K., Buckberry, S., Vargas-Landín, D. B., Pflueger, J., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/628347 · Cited by 10
Alzheimer's Factors in Ischemic Brain Injury
Pluta, R. M., & Jaboski, M. (2012) · InTech eBooks · doi:10.5772/27205 · Cited by 10
“…from blood to brain tissue (Dickstein et al., 2006) and significantly improving reverse transport from brain into blood plasma (Pluta et al., 2000; Bell et al., 2009) and preventing ischemic events in neurons (Pluta 2007c see for references) are principal main future points in treatment of…”
BackgroundAu, D. T., Arai, A. L., Fondrie, W. E., Muratoglu, S. C., & Strickland, D. K. (2018) · Current Drug Targets · doi:10.2174/1389450119666180511162048 · Cited by 10
Cheng, X.-Y., Li, S.-Y., Mao, C.-J., Wang, M.-X., Chen, J., Wang, F., Wang, G., Deng, W., Li, X., & Liu, C. (2017) · Neuroscience · doi:10.1016/j.neuroscience.2017.11.040 · Cited by 8
“Altered SRF expression has been reported and implicated in the pathogenesis of several neurodegenerative disorders, such as Alzheimer’s disease and Huntington’s disease (Chow et al., 2007; Bell et al., 2009; Beck et al., 2012).”
Background
Metadata
- Authors
- Bell, R. D., Deane, R., Chow, N., Long, X., Sagare, A., Singh, I., Streb, J. W., Guo, H., Rubio, A., Van Nostrand, W., Miano, J. M., & Zlokovic, B. V.
- Affiliations
- University of Rochester Medicine (US)
- Venue
- Nature Cell Biology
- Published
- 2008-12-21
- Volume
- 11
- Issue
- 2
- Pages
- 143-153
- ISSN
- 1465-7392 (ISSN-L)
- 1476-4679
- PMC
- PMC2654279
- OpenAlex
- W2094117787
- Cited by
- 261
- References
- 52
- Citations by year
- 2026: 5 · 2025: 10 · 2024: 10 · 2023: 9 · 2022: 12 · 2021: 10 · 2020: 9 · 2019: 12 · 2018: 6 · 2017: 19 · 2016: 12 · 2015: 19 · 2014: 20 · 2013: 17 · 2012: 29
- FWCI
- 14.03
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Cell Biology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Chinese Academy of Agricultural Sciences
- National Institutes of Health
- National Institute on Aging (R37AG023084, R42AG026950, 1R43 AG02400)
- National Heart, Lung, and Blood Institute (R01HL132574, HL 62572, R01HL062572, R01HL091168)
- National Institute of Neurological Disorders and Stroke (R37NS034467, R01NS034467, R37NS34467)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- serum response factor, myocardin, LRP1, amyloid-beta clearance, cerebral amyloid angiopathy, Alzheimer's disease, SREBP2, cerebral hypoxia, transcriptional regulation
- MeSH terms
- Myocardin, Aged, Aged, 80 and over, Alzheimer Disease, Animals, Blood-Brain Barrier, Cells, Cultured, Cerebral Arteries, Disease Models, Animal, Female, Humans, Male, Mice, Transgenic, Muscle, Smooth, Vascular, Nuclear Proteins, Transcriptional Activation, Trans-Activators, Down-Regulation, Amyloid beta-Peptides, Serum Response Factor, Low Density Lipoprotein Receptor-Related Protein-1, Mice, Sterol Regulatory Element Binding Protein 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.